Additional Information

Description

Tadalafil Liquid Suspension 10 mg/mL is a phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). It enhances the effects of nitric oxide by inhibiting PDE5, resulting in increased cyclic guanosine monophosphate (cGMP), smooth muscle relaxation, and improved blood flow in target tissues.

This formulation carries potential risks including hypotension, prolonged erection (priapism), and visual disturbances. Patients must be monitored closely for cardiovascular status, particularly when initiating therapy or adjusting doses. Use is contraindicated in individuals with a known hypersensitivity to tadalafil or those concurrently receiving nitrate therapy due to the risk of severe hypotension.

Caution is advised when co-administered with alpha-blockers or CYP3A4 inhibitors, as these combinations can alter plasma concentrations and potentiate adverse effects. Tadalafil suspension should be stored in a cold environment and kept away from direct light. It is not recommended for use in patients with severe hepatic impairment.